Targeting the METTL3/YTHDF3/m6A/PGK1 axis to combat Choriocarcinoma progression
Archives of Biochemistry and Biophysics · 2025
DOI: 10.1016/j.abb.2025.110550 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Biochemistry and Biophysics, 2025. Verfasst von Dongjie Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynaecology, The First People's Hospital of Yunnan Province, Kunming, China; The Affiliated Hospital of Kunming University of Science a…. Hauptthemen laut MEDLINE: Methyltransferases, Phosphoglycerate Kinase, Choriocarcinoma, RNA-Binding Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Kunming Medical University, Yunnan Provincial Science and Technology Department.
Abstract (Originalsprache)
Choriocarcinoma (CC) is a highly aggressive trophoblastic tumor characterized by rapid progression and early metastasis. Glycolysis, a crucial metabolic pathway in cancer, is essential for tumor growth, yet its specific role in CC is not well understood. Phosphoglycerate kinase 1 (PGK1), an important enzyme in glycolysis, along with N6-methyladenosine (m6A) RNA methylation, a common modification of mRNA, are both associated with tumorigenesis. However, the role of m6A-modified PGK1 in CC has not been investigated. In this study, bioinformatics analysis has identified PGK1 as a key regulator in the progression of CC and glycolysis. PGK1 was found to be upregulated in CC cell lines BeWo and JEG-3 cells. Functional experiments indicated that PGK1 knockdown suppressed proliferation and glycolysis of tumor cells, and inhibited tumor growth in xenograft mouse models. Mechanistically, the m6A modification of PGK1 mRNA, mediated by methyltransferase-like 3 (METTL3), increased its stability, while YTH domain-containing family protein 3 (YTHDF3) promoted its translation in an m6A-dependent manner. Silencing PGK1 diminished tumor progression, while the overexpression of METTL3 or YTHDF3 partially mitigated these effects by restoring PGK1 expression and glycolytic function. Overall, the METTL3/YTHDF3 axis enhanced CC progression by stabilizing PGK1 mRNA through m6A modification. These results position PGK1 as a potential diagnostic biomarker and therapeutic target, indicating that targeting the METTL3/YTHDF3/m6A/PGK1 pathway may provide innovative strategies for the treatment of CC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gynaecology, The First People's Hospital of Yunnan Province, Kunming, China; The Affiliated Hospital of Kunming University of Science and Technology, Kunming, China. Electronic address: wangdongjie202204@1…
- Department of Gynaecology, The First People's Hospital of Yunnan Province, Kunming, China; The Affiliated Hospital of Kunming University of Science and Technology, Kunming, China. Electronic address: 318514466@qq.com.
- Department of Gynaecology, The First People's Hospital of Yunnan Province, Kunming, China; The Affiliated Hospital of Kunming University of Science and Technology, Kunming, China. Electronic address: f3178161196@163.com.
- Department of Gynaecology, The First People's Hospital of Yunnan Province, Kunming, China; The Affiliated Hospital of Kunming University of Science and Technology, Kunming, China. Electronic address: tss19861225@163.com.
- Department of Gynaecology, The First People's Hospital of Yunnan Province, Kunming, China; The Affiliated Hospital of Kunming University of Science and Technology, Kunming, China. Electronic address: 15925156181@163.com.
Förderung
- National Natural Science Foundation of China
- Kunming Medical University
- Yunnan Provincial Science and Technology Department
Zitieren
APA
Wang, D., Meng, C., Fan, J., Tang, S., & Fang, J. (2025). Targeting the METTL3/YTHDF3/m6A/PGK1 axis to combat Choriocarcinoma progression. Archives of Biochemistry and Biophysics. https://doi.org/10.1016/j.abb.2025.110550
Vancouver
Wang D, Meng C, Fan J, Tang S, Fang J. Targeting the METTL3/YTHDF3/m6A/PGK1 axis to combat Choriocarcinoma progression. Archives of Biochemistry and Biophysics. 2025. doi:10.1016/j.abb.2025.110550
BibTeX
@article{Wang2025,
author = {Wang, Dongjie and Meng, Chunmei and Fan, Juan and Tang, Shunsong and Fang, Junfeng},
title = {Targeting the METTL3/YTHDF3/m6A/PGK1 axis to combat Choriocarcinoma progression},
journal = {Archives of Biochemistry and Biophysics},
year = {2025},
doi = {10.1016/j.abb.2025.110550}
}
EUVIMED